ImmunoScape
Illuminating the Immune Landscape
Illuminating the Immune Landscape
ImmunoScape is a pre-clinical biotechnology company based in Singapore, founded in 2016. The company is dedicated to advancing next-generation TCR cell therapies in the field of oncology, leveraging its proprietary Deep Immunomics technology platform. This innovative platform allows for highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across various solid tumors.
With multiple discovery programs underway, ImmunoScape is making strides towards IND-enabling studies and eventual entry into clinical trials. The company recently secured a significant $14.00M Venture Round investment on 20 September 2022, with leading investors including Amgen Ventures, Anzu Partners, and EDBI.
As ImmunoScape continues to illuminate the immune landscape and make notable advancements in TCR cell therapies, it remains a compelling player in the biotechnology industry, poised for future growth and impact in the field of oncology. To stay updated on their progress, visit immunoscape.com and follow them on Twitter at @immunoscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $14.00M | 3 |
|
20 Sep 2022 |
| Venture Round | $14.00M | 3 |
|
14 Apr 2021 |
| Venture Round | $11.00M | 3 |
|
12 Aug 2020 |
| Seed Round | ¥340.00M | 1 |
|
26 Oct 2018 |
No recent news or press coverage available for ImmunoScape.
We care about your data, and we'd love to use cookies make your experience better.
